Well, absolutely. But that's the point — the staff are interested in the most clinically competitive therapy, which is still being shaken out. The steroid studies confirm a significant competitor, perhaps expanding/consolidating that treatment choice. This is worth examining from an investment point of view.
Which is the reason this platform exists.
And keeping in mind that competition is frequently hostile, if competitors can derail the adoption of cellular therapies they will. I want this option in ICU. That's another reason for keeping all risks on our radar.
Well, absolutely. But that's the point — the staff are...
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |